Other Clinical Trial - Study of the Link Between Psychosocial Treatments &

Status Completed

Clinical Trial Summary

The Attention Deficit and Hyperactivity Disorder (ADHD) is a frequent disorder in children and adolescents. The diagnosis is clinical with the input of several informants (child, family, teachers, …). ADHD is a risk factor for academic difficulties, school dropout, social isolation, injury, oppositional behaviour. In school-age children and adolescents having moderate to high or persistent impairment despite psycho-educational support and environmental modification, the first-line treatment is methylphenidate. Group or individual cognitive behavioural therapy for parents and/or children and adolescents is recommended for co-occurring disorders and persistent impairment. In France, the initiation of methylphenidate requires an annual hospital prescription by a paediatrician or psychiatrist, and a regular medical supervision (weight, heart rate, blood pressure, …). At least once a year, the indication of methyphenidate needs to be re-evaluated and confirmed at the hospital. In case of lack of efficiency and/or poor tolerance, therapeutic alternatives including non-psychostimulants should be considered.

A randomized controlled trial evaluated the dose of methylphenidate received over a period of 13 months. It was observed that the "combined treatment" group (methylphenidate + psychosocial treatments) received a lower average dose of methylphenidate than the "methylphenidate alone" group. These results are difficult to extrapolate to the general population, due to the study protocol (regular monitoring of ADHD symptoms with the aim of total remission).

For a global consideration of children's needs, it is important to better understand the interactions between these two therapeutic approaches.

To participate in the study, parents will have to complete an online questionnaire. This questionnaire contains anamnestic data collection, questionnaires to assess ADHD symptoms and parenting practices.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Attention Deficit Disorder with Hyperactivity
Attention Deficit Hyperactivity Disorder
Hyperkinesis
Youths

Clinical Trial Details

NCT number	NCT04412499
Study type	Observational
Source	University Hospital, Montpellier
Contact
Status	Completed
Phase
Start date	May 1, 2020
Completion date	June 30, 2020

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT06129396` - Effects of Aerobic Exercise Intervention in Adolescents With Attention-deficit/Hyperactivity Disorder (ADHD)	N/A
Completed	`NCT04779333` - Lifestyle Enhancement for ADHD Program 2	N/A
Recruiting	`NCT05935722` - Evaluation of a Home-based Parenting Support Program: Parenting Young Children	N/A
Completed	`NCT03148782` - Brain Plasticity Underlying Acquisition of New Organizational Skills in Children-R61 Phase	N/A
Completed	`NCT04832737` - Strength-based Treatment Approach for Adults With ADHD	N/A
Recruiting	`NCT04631042` - Developing Brain, Impulsivity and Compulsivity
Recruiting	`NCT05048043` - Development of a Game-supported Intervention	N/A
Completed	`NCT03337646` - Evaluation of the Effect and Safety of Lisdexamfetamine in Children Aged 6-12 With ADHD and Autism	Phase 4
Not yet recruiting	`NCT06454604` - Virtual Reality Treatment for Emerging Adults With ADHD	Phase 2
Not yet recruiting	`NCT06406309` - Settling Down for Sleep in ADHD: The Impact of Sensory and Arousal Systems on Sleep in ADHD	N/A
Not yet recruiting	`NCT06080373` - Formulation-based CBT for Adult Inmates With ADHD: A Randomized Controlled Trial	N/A
Completed	`NCT02477280` - Effects of Expectation, Medication and Placebo on Objective and Self-rated Performance	Phase 4
Completed	`NCT02911194` - a2 Milk for Autism and Attention-deficit Hyperactivity Disorder (ADHD)	N/A
Completed	`NCT02473185` - Effects of Expectation, Medication and Placebo on Objective and Self-rated Performance During the QbTest	Phase 4
Completed	`NCT02780102` - Cognitive-Motor Rehabilitation, Stimulant Drugs, and Active Control in the Treatment of ADHD	N/A
Completed	`NCT02390791` - New Technologies to Help Manage ADHD	N/A
Completed	`NCT02555150` - A Comparison of PRC-063 and Lisdexamfetamine in the Driving Performance of Adults With ADHD	Phase 3
Completed	`NCT02829970` - Helping College Students With ADHD Lead Healthier Lifestyles	N/A
Recruiting	`NCT04175028` - Neuromodulation of Executive Function in the ADHD Brain	N/A
Recruiting	`NCT04296604` - Transcranial Direct Current Stimulation (tDCS) Neuromodulation of Executive Function Across Neuropsychiatric Populations	N/A

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Study of the Link Between Psychosocial Treatments and the Need of Pharmacological Treatments in Children With Attention Deficit Hyperactivity Disorder — OPTIME-TDAH

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms